1. Morbidity and Mortality Weekly Report (MMWR). (2007). Quadrivalent human papillomavirus vaccine. CDC, 56(RR02), 1–24. www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm .
2. Morbidity and Mortality Weekly Report (MMWR). (2010). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). CDC, 59(20), 626–629. www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm .
3. Morbidity and Mortality Weekly Report (MMWR). (2007). QuickStats: Prevalence of HPV infection among sexually active females aged 14–59 years by age group. National Health and Nutrition Examination Survey, United States 2003–2004. CDC. www.cdc.gov/mmwr/preview/mmwrhtml/mm5633a5.htm .
4. Weaver, B., Shew, M., Qadadri, B., et al. (2011). Natural history of multiple human papillomavirus infections in female adolescents with prolonged follow-up. Journal of Adolescent Health, 48(5), 473–480.
5. Morbidity and Mortality Weekly Report (MMWR). (2010). National, state, and local area vaccination coverage among adolescents aged 13–17 years—United States, 2009. CDC, 59(32):1018–1023. www.cdc.gov/mmwr/preview/mmwrhtml/mm5932a3.htm?s_cid=mm5932a3_e%0d%0a .